|
April 2010
Getting the Deal Through - Vertical Agreements 2010
Sidley lawyers wrote four of the chapters in this year's edition of "Getting the Deal Through — Vertical Agreements," a book recently published by Global Competition Review. The book is intended for in-house counsel and provides an overview of antitrust regulation of distribution arrangements in 42 jurisdictions worldwide.
|
|
Reports
|
|
Summer 2009
The Dragon Rises: China’s Merger Control Regime One Year On
Antitrust, an ABA Magazine
Coming into effect with the Olympic fanfare of August 2008, the Anti-Monopoly Law (AML) of the People’s Republic of China is now settling into the mundane world of case-specific analysis and decision. The approaching anniversary of the AML’s effective date provides an opportunity to review how the AML has developed during these first 12 months.
|
|
Articles
|
|
March 2009
Getting the Deal Through - Vertical Agreements 2009
Sidley lawyers wrote four of the chapters in this year's edition of "Getting the Deal Through — Vertical Agreements," a book recently published by Global Competition Review. The book is intended for in-house counsel and provides an overview of antitrust regulation of distribution arrangements in 41 jurisdictions worldwide.
|
|
Books
|
|
2008/09
China - Compensation for Drug and Device-Related Injuries
PLC Cross-border Life Sciences Handbook
As China develops into one of the leading manufacturers for pharmaceutical and medical device products in the world, it must increasingly contend with what other nations have encountered over the past decades: finding the right way to compensate patients when they suffer from injuries that may have been related to the use of a drug or device product.
|
|
Articles
|
|
December 1, 2008
Emerging Antitrust Regimes In Asia
Law360
This summer's implementation of China's Anti-Monopoly Law (AML) may well stimulate the emergence and modernization of other antitrust regimes in Asia.
|
|
Articles
|
|
September 22, 2008
Insider Analysis from Sidley Austin LLP: Market Definition in Life Sciences Sector Under the Chinese Anti-Monopoly Law
PharmAsia News
China's Anti-Monopoly Law, in force since Aug. 1, raises difficult questions for market players in the health care industry in China. One issue of particular importance is how to define the "relevant market" for medicinal products.
|
|
Articles
|
|
|